Home
Live Updates
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) : vimarsana.com
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025) Multiple Secondary Symptom Endpoints Met, Statistical...
Related Keywords
United States ,
American ,
,
Securities Exchange ,
Company To Host Conference Call ,
Palatin Technologies Inc ,
Prnewswire Palatin Technologies Inc ,
Intent To Treat Analysis ,
Co Primary Symptom Endpoint Met ,
Statistical Significance ,
Secondary Symptom Endpoints Met ,
Co Primary Sign Endpoint ,
Secondary Sign Endpoints Not ,
Superiority Over Vehicle ,
Multiple Sign ,
Discussions Planned ,
Regulatory Approval ,
Host Conference Call ,
Conference Call ,
Eastern Time ,
Participant Access Code ,
Replay Passcode ,
Dry Eye Disease ,
Market Scope ,
Eye Product Market Review ,
Melanocortin Receptor Agonists ,
Palatin Technologies ,
Securities Act ,
Securities Exchange Act ,
Private Securities Litigation Reform Act ,
vimarsana.com © 2020. All Rights Reserved.